The Supportive Care Strategy Group (SCSG) focuses on the better standardization of supportive care practices.

 

May lead to improved results / interpretability of other therapeutic trials, where supportive care guidelines are often listed as: “Per institutional practices”

• Viral Pathogens: CMX-001

• Young Children: TBI & Neurocognitive Outcomes

• Prospective Neurocognitive Evaluation

• Skeletal Toxicity

• Need to better define the field of late effects following HCT for children

 

Types of studies from the SCSG will include:

• PTCTC Core Trials

• Partnership Trials

• Facilitated Trials

 

All trials must undergo Scientific Review and final approval by the Executive Committee. Successful trials need:

• Strong interest from the community

• Dedicated committee members

• Appropriate reimbursement